Effects of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma patients after autologous peripheral blood hematopoietic stem cell transplantation

白血病·淋巴瘤 Pub Date : 2020-03-25 DOI:10.3760/CMA.J.CN115356-20190617-00117

Jin Zhao, L. Su, T. Guan, Jiangtao Wang, Xiaolan Liu, Li Ma

{"title":"Effects of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma patients after autologous peripheral blood hematopoietic stem cell transplantation","authors":"Jin Zhao, L. Su, T. Guan, Jiangtao Wang, Xiaolan Liu, Li Ma","doi":"10.3760/CMA.J.CN115356-20190617-00117","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effect of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma (NHL) patients after autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). \n \n \nMethods \nThe data of 60 NHL patients who underwent APBSCT from May 2010 to May 2016 in the Affiliated Cancer Hospital of Shanxi Medical University was retrospectively analyzed, including 32 B-NHL patients and 28 T-NHL patients. The patients were grouped according to the receiver operating characteristic curve (ROC) threshold, and the hematopoietic reconstruction after transplantation was analyzed. The relationship between the infused CD34+ cell count and prognosis was analyzed. The prognostic factors were analyzed using univariate and multivariate analyses. \n \n \nResults \nThe CD34+ cell count threshold was determined to be 4.35×106/kg based on ROC. In CD34+ cell count≥ 4.35×106/kg group (20 cases) and CD34+ cell count 60 years old, Ann Arbor stage Ⅲ-Ⅳ, international prognostic index (IPI) score > 2 and infused CD34+ cell count < 4.35×106/kg (all P < 0.05). Multivariate analysis showed that IPI score and infused CD34+ cell count were both independent predictive factors of PFS (RR = 0.333, 95% CI 0.112-0.994, P = 0.049; RR = 0.190, 95% CI 0.047-0.773, P = 0.020), and IPI score was an independent predictive factor of OS (RR = 0.095, 95% CI 0.011-0.837, P = 0.034). \n \n \nConclusion \nThe infused CD34+ cell count affects the hematopoietic reconstruction time and component blood transfusion after APBSCT, and has certain predictive value for the prognosis of NHL patients. \n \n \nKey words: \nLymphoma, non-Hodgkin; Autologous hematopoietic stem cell transplantation; CD34+ cell count","PeriodicalId":16246,"journal":{"name":"白血病·淋巴瘤","volume":"29 1","pages":"165-169"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"白血病·淋巴瘤","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115356-20190617-00117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the effect of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma (NHL) patients after autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). Methods The data of 60 NHL patients who underwent APBSCT from May 2010 to May 2016 in the Affiliated Cancer Hospital of Shanxi Medical University was retrospectively analyzed, including 32 B-NHL patients and 28 T-NHL patients. The patients were grouped according to the receiver operating characteristic curve (ROC) threshold, and the hematopoietic reconstruction after transplantation was analyzed. The relationship between the infused CD34+ cell count and prognosis was analyzed. The prognostic factors were analyzed using univariate and multivariate analyses. Results The CD34+ cell count threshold was determined to be 4.35×106/kg based on ROC. In CD34+ cell count≥ 4.35×106/kg group (20 cases) and CD34+ cell count 60 years old, Ann Arbor stage Ⅲ-Ⅳ, international prognostic index (IPI) score > 2 and infused CD34+ cell count < 4.35×106/kg (all P < 0.05). Multivariate analysis showed that IPI score and infused CD34+ cell count were both independent predictive factors of PFS (RR = 0.333, 95% CI 0.112-0.994, P = 0.049; RR = 0.190, 95% CI 0.047-0.773, P = 0.020), and IPI score was an independent predictive factor of OS (RR = 0.095, 95% CI 0.011-0.837, P = 0.034). Conclusion The infused CD34+ cell count affects the hematopoietic reconstruction time and component blood transfusion after APBSCT, and has certain predictive value for the prognosis of NHL patients. Key words: Lymphoma, non-Hodgkin; Autologous hematopoietic stem cell transplantation; CD34+ cell count

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

输注CD34+细胞计数对非霍奇金淋巴瘤患者自体外周血造血干细胞移植后造血恢复及预后的影响

目的探讨CD34+细胞计数对非霍奇金淋巴瘤（NHL）患者自体外周血造血干细胞移植（APBSCT）后造血功能恢复及预后的影响。方法回顾性分析2010年5月至2016年5月在山西医科大学附属癌症医院接受APBSCT的60例NHL患者的资料，其中B-NHL患者32例，T-NHL患者28例。根据受试者操作特征曲线（ROC）阈值对患者进行分组，并分析移植后的造血重建情况。分析输注CD34+细胞计数与预后的关系。预后因素采用单因素和多因素分析。结果根据ROC测定CD34+细胞计数阈值为4.35×106/kg。106／kg组（20例）和60岁Ann ArborⅢ～Ⅳ期CD34＋细胞，国际预后指数（IPI）评分>2，输注CD34+细胞计数<4.35×106/kg（均P<0.05）。多因素分析显示，IPI评分和输注CD34+-细胞计数均为PFS的独立预测因素（RR=0.33，95%CI 0.112-0.994，P=0.049；RR=0.190，95%CI 0.047-0.773，P=0.020），IPI评分是OS的独立预测因素（RR=0.095，95%CI0.011-0.837，P=0.034）。结论输注CD34+细胞计数影响APBSCT后造血重建时间和成分输血，对NHL患者的预后有一定的预测价值。关键词：淋巴瘤，非霍奇金；自体造血干细胞移植；CD34+细胞计数

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

白血病·淋巴瘤 Medicine-Oncology

自引率

0.00%

发文量

6278

期刊介绍： The JLL is a specialized academic journal that carries articles on hematological malignancies, and mainly about leukemia and lymphoma, involving the fields of medicine, chemistry, biology, etc. The purposes are to reflect the scientific results and the academic trends in the hematological malignancy field. It paid attention on both the basic research and clinical work, but more on the clinical side; on combining popularization with the raising of standards, but more on the raising of standards, in order to provide a field for exchanging experience, inspiring mutually and linking up information for those working for the basic research and clinical diagnosis and treatment in the field of leukemia and lymphoma. It is intended for high and middle ranking medical staffs.